research centers


Search results: Found 31

Listing 1 - 10 of 31 << page
of 4
>>
Sort by

Article
Role of Ezetimibe in Combination with Statins(Simvastatin and Atorvastatin) in Controlling Dyslipidemia

Authors: Gamal A.Abdulbari --- Shatha H. Ali شذى حسين علي --- Falah H.Al-Malki
Journal: Iraqi Journal of Pharmaceutical Sciences المجلة العراقية للعلوم الصيدلانية ISSN: 16833597 Year: 2009 Volume: 18 Issue: 1 Pages: 1-12
Publisher: Baghdad University جامعة بغداد

Loading...
Loading...
Abstract

Cardiovascular risk is independently increased by plasma lipids abnormalities (low- density and high density lipoprotein -cholesterol and triglycerides). Most patients have more than one lipid abnormality. Combination therapy with lipid-modifying agents could offer an important therapeutic option for improving the overall lipid profile. Combinations have demonstrated to provide additive efficacy and significant reductions in coronary events . This study was designed to evaluate the effect of ezetimibe, when used in combination with other hypolipidaemic agents ( statins) on lipid profile as well as on liver function ,renal function, oxidative stress, and platelets function when given to dyslipidaemic patients . Forty four patients (24 males and 20 females) with age ranged between 40-70 years (54 ±14.6) with dyslipidaemia on statins therapy for at least 6 month were involved in this clinical trials. They were randomized into two groups treated with either a combination of 20 mg/day simvastatin or a combination of 20mg/day atorvastatin and 10mg/day of ezetimibe.The study also included 22 apparently healthy subjects with age ranged (40-70years) and sex(11males and 11 females) matching that of the patients group. Serum lipid profile (total cholesterol -TC, triglycerides -TG, low density lipoprotein-cholesterol –LDL-C, very low density lipoprotein-cholesterol-VLDL-C, and high density lipoprotein-cholesterol –HDL-C), oxidative stress marker (Malondialdehyde-MDA), liver functions indices (Alanin aminotransferase -ALT,Aspartate aminotransferase- AST, total bilirubin), renal function parameters (urea, creatinine, and microalbuminuria) and platelets function test (bleeding time)were evaluated before and after 4 and 6 weeks of starting ezetimibe treatment . Treatment with ezetimibe plus simvastatin or atrovostatin resulted in significant lowering in TC, TG, LDL-C levels with elevation in HDL-C also the LDL/HDL ratio lowered significantly ( by 38.16%). This effect was associated with significant changes in liver function , and oxidative stress without changes in platelets function nor in renal function. The results presented in this study indicated that ezetimibe can be used in clinical practice for the treatment of dyslipidaemia, when combined with other hypolipidaemic agents like simvastatin and atorvastatin to improve the therapeutic profile with ameliorating some of their adverse effects.

ان خطر أمراض الأوعية القلبية يمكن إن يزداد بصورة غير معتمدة عند الاختلال في الدهون الثلاثية والدهون البروتينية عالية الكثافة وواطئة الكثافة. وجد ان معظم المرضى لهم أكثر من خلل واحد في الدهون. ان العلاج المركب من المواد المعدلة للدهون يوفر فائدة علاجية مهمة لتحسين كل مستويات الشحوم في الدم . و العلاج المركب يمكن ان يكون له فعالية إضافية مسبباً هبوطاً معنوياً في التأثيرات على الشرايين التاجية. أجريت هذه الدراسة وصممت لتقييم فعالية الايزتايمب مع مواد خافضة للدهون مثل الستاتينات على معايير الكيمياء الحياتية والمتمثلة بمستويات ايض الدهون و فرط الأكسدة ووظائف الكبد والكلى ، إضافة إلى تأثيره على وظائف الصفيحات الدموية (زمن النزف) ومقارنة هذه التأثيرات مع أدوية تقليدية خافضة للدهون (سمفاستاتين و اتورفستاتين) كنظام مختلط مع الازيتياميب عند مرضى الشحام .اشتملت هذه الدراسة على (44) مريضا (24 ذكور، 20 اناث) بعمر يتراوح بين (40-70) سنة وبمعدل 54± 14.6 مريضاً بداء الشحام مستمرين على العلاج بادوية الستاتين. تم تقسيم المرضى عشوائياً الى مجموعتين كالأتي:المجموعة الأولى: هي مجموعة المرضى الذين استخدموا نظام مختلط بين السمفاستاتين والايزيتايميب 20+10 ملغم يومياً والمجموعة الثانية على نظام مختلط بين الاتورفاستاتين والايزيتايميب 20+10 ملغم يومياً. استمرت فترة المتابعة ستة أسابيع متتالية. كذلك ضمن الدراسة مجموعة مقارنة من الأصحاء بأعمار مقاربة وبنفس توزيع الجنس لمجاميع المرضى بالشحام وبعدد (22). تم قياس مستويات الشحوم في الدم (TC,TG,HDL,LDL) ومعايير فرط الاكسدة المالوندالديهايد ووظائف الكبد (AST,ALT T.Bil.) ووظائف الكلى (S.Urea,creatinine,MAU) ووظائف الصفيحات الدموية (Bleeding Time) قبل اعطاء العلاج وبعد مرور 4 اسابيع من اعطاء الازيتاميب. اظهرت تحاليل البيانات فروقا معنوية واضحة للازيتاميب مع السمفاستاتين او الاتروفاستاتين على مستوى شحوم الدم حيث لوحظ حصول انخفاض معنوي في تراكيز (TC,TG&LDL) وارتفاع مستوى HDL وانخفاض ملحوظ في نسبةترافق مع تغير معنوي في وظائف الكبد ALT,AST,T.Bil. . كذلك ظهر تحسن معنوي في معايير فرط الاكسدة متمثلة بانخفاض مستوى MD A و لم يتم ملاحظة أي تأثيرات ظاهرة او سلبية ذات دليل معنوي لوظائف الكلى والكبد والصفيحات الدموية.في ضوء النتائج التي افرزتها هذه الدراسة يمكن استنتاج مايلي :ان الازيتاميب يمكن ان يستخدم كعلاج اضافي بكفاءة لعلاج مرض الشحام وعندما يؤخذ مع ادوية خافضة للكوليسترول كالسمفاستاتين والاتروفاستاتين يمكن ان يحسن الفائدة العلاجية ومنع التأثيرات الجانبية المتوقعة.


Article
The Effect of Methyl dopa on serum lipid profile in rat

Author: Laith Mohammed Abbass AL-Hussueni ليث محمد عباس
Journal: Al-Qadisiyah Medical Journal مجلة القادسية الطبية ISSN: 18170153 Year: 2007 Volume: 3 Issue: 4 Pages: 85-92
Publisher: Al-Qadisiyah University جامعة القادسية

Loading...
Loading...
Abstract

Evidence liking hypertension and dyslipidemia are very important in deciding which antihypertensive drug is going to be describe to hypertensive patient who had or at risk to had dyslipidemia. Antihypertensive drugs which have neutral effect or preferably beneficial effect on lipid profile are the first choice in those patients. Drugs with harmful effect on serum lipid profile may add another problem to the patient and increase the risk of complications. Purpose: This study is carried on to evaluate the effect of methyl dopa on serum lipid profile. Methods: Twenty rats enrolled in the experiment given atherogenic diet for twelve weeks then randomly divided into two groups, first group received 33 mg /Kg /day P. O Methyl dopa dissolved in 2 ml distilled water given by nasogastric tube twice daily and serve as central group. The treatment continues with atherogenic diet for another twelve weeks. The serum lipid profile namely triglyceride, total cholesterol, LDL-cholesterol (low density lipoprotein cholesterol) HDL-cholesterol (high density lipoprotein cholesterol) and HDL-cholesterol / total cholesterol ratio were estimated before and after the treatment. The statistical analysis was done using ANOVA with level of significance P<0.05. Result: Methyl dopa was found to have no effect on serum triglyceride level and on total cholesterol serum level but it causes significant decrease in LDL-cholesterol serum level and significant increase in HDL- cholesterol serum level in comparison to control group. Conclusion: Methyl dopa has beneficial effect on serum lipid profile as it causes decrease in LDL-cholesterol level which is the atherogenic portion of cholesterol and causes increase in HDL-cholesterol level which is the protective portion of cholesterol. This effect justify it's use in patients who have or at risk to have dyslipidemia.

استهدفت هذه الدراسة معرفة تأثير دواء مثيل دوبا المستخدم في علاج ارتفاع ضغط الدم على مستوى الدهون في مصل الدم لدى الجرذان بسبب وجود ارتباط وثيق بين ارتفاع ضغط الدم وبين ارتفاع مستوى الدهون وبالتالي يتحتم علينا اختيار دواء لا يؤدي إلى زيادة الاضطراب في مستوى الدهون. عشرون جرذاً استخدمت في التجربة أعطيت غذاء عالي الكولسترول لمدة اثنا عشر أسبوعاً ومن ثم قسمت إلى مجموعتين الأولى: أُعطيت (33) ملغرام/ كغم/ اليوم من دواء مثيل دوبا عن طريق الفم مرتين في اليوم. والمجموعة الثانية: أعطيت ماء مقطر واعتبرت مجموعة سيطرة. العلاج استمر لمدة اثنا عشر أسبوع مع الغذاء عالي الكولسترول أيضاً. مستوى الدهون في مصل الدم تم قياسه قبل وبعد البدء بالعلاج وكانت النتائج كالأتي: لم يكن لدواء مثيل دوبا تأثير على الكلسيريدات الثلاثية ولا على ولا على الكولسترول الكلي لكنه سبب نقصان ملحوظ في مستوى الكولسترول واطئ الكثافة وسبب زيادة في مستوى الكولسترول عالي الكثافة بالمقارنة مع مجموعة السيطرة الأمر الذي يظهر فائدة كبيرة في استخدام هذا الدواء للمرضى الذين يعانون من ارتفاع ضغط مع اضطراب مستوى الدهون لديهم.


Article
Dyslipidemia among patients with type 2 diabetes mellitus visiting Specialized Center for Diabetes and Endocrinology

Author: aDr.Badri Fadhil: MBchB , CABM , bDr. Mohammed Abdul Jabbar : MBchB , CABM
Journal: Al-Kindy College Medical Journal مجلة كلية الطب الكندي ISSN: 18109543 Year: 2014 Volume: 10 Issue: 1 Pages: 18-25
Publisher: Baghdad University جامعة بغداد

Loading...
Loading...
Abstract

Background:The most common pattern of dyslipidemia in diabetic patients is increased triglyceride (TG) and decreased HDL cholesterol level, The concentration of LDL cholesterol in diabetic patients is usually not significantly different from non diabetic individuals, Diabetic patients may have elevated levels of non-HDL cholesterol [ LDL+VLDL]. However type 2 diabetic patients typically have apreponderance of smaller ,denser LDL particles which possibly increases atherogenicity even if the absolute concentration of LDL cholesterol is not significantly increased. The Third Adult Treatment Panel of the National Cholesterol Education Program (NCEP III) and the American Heart Association (AHA ) have designate diabetes as a coronary heart disease (CHD) equivalent and recommended treatment of LDL-c to < 2.6 mmoll (<100 mgldl)Objectives: We assessed the treatment ,type and control of dyslipidemia among adults with diabetes mellitus.Methods:This is a prospective study conducted in the Neurosurgical Hospital in Baghdad, Iraq, during the period from January 1999 to January 2001. Any patient admitted during the period of the study with clinical history, signs, symptoms, and contrast enhanced MRI suggesting a cerebral glioma and confirmed by postoperative histopathological results of glioma has been included in this study. While multifocal lesions, long-lasting epilepsy, use of antiepileptic therapy, multiple cranial lesions, previous cranial surgery, any chronic illness, and histopathological result of other tumors were exclusion criteria. All patients were at their first operation for brain tumors. Patients were examined by analyzing several functional domains (intelligence, executive functions, memory, language, praxis, gnosis and mood state) in order to establish the effect of tumor and surgery on cognition.Results:29 patients who fulfilled the selection criteria were included. Mean duration of clinical history was 5 months (range 1–9 months). At baseline, using test- and domain-based criteria, 79% and 38% of patients, respectively, were impaired, the former related to tumor factors such as edema (P <0.05), larger size (P <0.05) and higher grade (P = 0.001). Verbal memory, visuospatial memory and word fluency were the most frequently affected functions, partly associated with depression. Postoperatively, 38% and 55% of patients, respectively, were unchanged, 24% and 21% improved, and 38% and 24% worsened; 24% and 62% of patients were intact, respec¬tively.Conclusions:The extent of removal did not influence the outcome. Improvement involved previously impaired functions and was correlated with high-grade tumors. Worsening regar-ded executive functions was related to tumor size and was partly explained by radiological findings on postoperative MRI. This prospective study, focusing on the effects of tumor and surgery, showed that tumor significantly affects cognitive func¬tions, mainly due to the mass effect and higher grading. Surgical treatment improved the functions most frequently affected preoperatively and caused worsening of execu¬tive functions soon after operation, leaving the overall cognitive burden unchanged and capable of improvement prospectively.


Article
A study on the Prevalence of Dyslipidemic Disorder Among Residents of Karbala City

Authors: Hedef Dhafir El-Yassin --- Zainab Abdul Razak Al- Sharifi --- Suhair Al-Jeboori
Journal: Iraqi Academic Scientific Journal المجلة العراقية للاختصاصات الطبية ISSN: 16088360 Year: 2011 Volume: 10 Issue: 3 Pages: 358-366
Publisher: The Iraqi Borad for Medical Specialization المجلس العراقي للاختصاصات الطبية

Loading...
Loading...
Abstract

ABSTRACT:BACKGROUND:Dyslipidemia is a common health problem.OBJECTIVE:The present study was to estimate the prevalence of dyslipidemia as defined by the NCEP ATP3 criteria among people living in Karbala city.SUBJECTS AND METHODS:The investigations were performed on a sample of 130 subjects selected arbitrarily from those attending the public clinic in AL- Hussainy teaching hospital in Karbala for consultation and from some subjects accompanying the patients. Fasting blood samples for routine lipid analyses from each subject were obtained after informing them about the project and having their approval.RESULTS:In this sample of subjects it was found that 72.3% of them had a plasma TC level lower than 200mg/dl. This study also determined a prevalence of hypertriglyceridemias in 23.3% of study subjects who have a borderline TG level. The prevalence of high and very high TG among them were 6.9% and 4.4% respectively. The frequency of LDL-C levels above 160 mg/dl was found to be about 1% of the sample. Borderline levels of LDL-C was found in 7.3%of the sample. In the meantime the prevalence of low HDL-C levels in this study was found to be 39.2% of the subjects who had a serum level of HDL-C less than 40mg/dl.CONCLUSION:In conclusion this study demonstrated a very high prevalence of dyslipidemia among Iraqi adult subjects living in Karbala city. A public health strategy for prevention, detection and treatment of this disorder is neede


Article
Evaluation of periodontal status in type 2diabetic patients on statin therapy
تقييم حالة دواعم السن عند مرضى السكري من النوع الثاني الذين يعالجون بأدوية السـتاتينات

Loading...
Loading...
Abstract

Background: Dyslipidemia is prevalent in type 2 diabetes mellitus (DM). Statin drugs were first used to treat hypercholesterolemia and later to treat dyslipidemia particularly in DM. However, it was found that they also have an anti-inflammatory pleiotropic effect. Chronic periodontitis is a continuous inflammatory process whose progression is modulated by the presence of DM.Aim of study: To assess the association between the use of statin drugs and any improvement in periodontal status.Materials & methods: Eighty (40 males and 40 females) type 2 diabetic patients were enrolled in this study. Patients were selected consecutively but with consideration of sex and exclusion criteria to compose two groups: - Forty (20 males and 20 females) patients who were on a statin drug for at least six months and were assigned as the ( Statin group ).-Forty (20 males and 20 females) patients who received no statin drug at any time and were assigned as ( Non statin group ).Periodontal status was evaluated by periodontal disease index (PDI) which includes plaque, calculus, and periodontal components of this index.Assessment of glycemic control included serum glucose assay and HbA1c assay.Lipid profile assay included estimation of serum total cholesterol (TC), serum triglycerides (TG), high density lipoprotein cholesterol (HDL-C), and calculation of low density lipoprotein (LDL-C). Results: The difference between the mean levels of HbA1c in statin group and non statin group was statistically non significant (8.61±1.82% vs. 9.10±1.26% respectively). There were no significant differences between statin group and non statin group in regard to the mean levels of TC, HDL-C, and LDL-C. The mean level of TG was higher in statin group and the difference was statistically of high significance (151.10±55.02 vs. 122.43±34.39 mg/dl, P<0.01). The mean values of plaque, calculus, and periodontal disease index were lower in statin group than in non statin group. The difference in plaque index was statistically highly significant (1.31±.0.57 vs. 1.70±0.50, P<0.01), while the differences in calculus index and periodontal disease index were statistically significant (0.61±0.47 vs. 0.87±0.65, and 2.75±0.89 vs. 3.16±.0.78 respectively, P< 0.05).Conclusion: Diabetic patients on statin therapy exhibited fewer clinical signs of periodontal disease than those without statin therapy. Key words: Diabetes mellitus, Dyslipidemia, Statins, Periodontitis

الخلفية: أن شذوذ شحميات الدم هو حالة منتشرة في مرضى السكّري من النوعِ الثاني . أن ادوية الستاتينات ( Statins ) قد اَستعملت في البدايةًً لمعالجة فَرْطُ كوليستيرولِ الدَّم ولاحقاً لمُعَالَجَة شذوذ شحميات الدم خصوصاً في السكّري. لقد وُجِدَ بأنّ لهذه الادوية تأثيرات متعددة المظاهر و منها تأثيرها المُضادُّ للالْتِهاب ً. أن الْتِهابُ دَوَاعِمِ السِّنّ المُزمن هو عملية ألتهابية مستمرة يتأثر تقدمها بوجود السكري هدف الدراسةِ: تَقييم العلاقة بين إستعمالِ ادوية الستاتينات وأيّ تحسن في الْتِهابُ دَوَاعِمِ السِّنّ.المواد والطرق: ثمانون من مرضى السكري (40 ذكر و40 أنثى)قد سُجّلوا في هذه الدراسةِ. المرضى إختيروا لإعْداْد مجموعتين:- أربعون (20 ذكر و20 أنثى) من المرضى كَانوا يعالجون بادوية الستاتينات لستّة شهورِ على الأقل. - أربعون (20 ذكر و20 أنثى) من المرضى لم يعالجوا بأدوية الستاتينات. تم تقييم حالة دواعم السن باستخدام دالة مرض دواعم السن والتي تشتمل على دالة اللوحة السنية، دالة القلح أو التكلس السني، ودالة دواعم السن.أن تقدير تضبيط سكر الدم قد تضمن قياس الكلوكوز في مصل الدم والهيموغلوبينِ الغليكوزيلاتي في الدم. أن تقدير مرتسم الشحوم قد تضمن قياس الكوليسترول الكلي وثُلاَثِيُّ الغليسريد وكوليسترول البروتين ٌالشَحْمِيٌّ رَفيعُ الكَثافَة في مصل الدم وحساب كوليسترول البروتين ٌالشَحْمِيٌّ خفيض الكَثافَة. النَتائِج: كانت الفروقات بين متوسط مستويات الهيموغلوبينِ الغليكوزيلاتي في مجموعةِ مرضى السكري الذين يعالجون بأدوية الستاتينات مقابلْ مجموعةِ مرضى السكري الذين لا يعالجون بأدوية الستاتينات لايعتد بها أحصائيا ( 8.61 ± 1.82 % مقابل 9.1 ± 1.26 % على التوالي ). لم يكن هنالك فرق يعتد به أحصائيا في متوسط مستويات مكونات مرتسم الشحوم لمجموعتي الدراسة بأستثناء ثُلاَثِيُّ الغليسريد الذي كان أعلى في مجموعة مرضى السكري الذين يعالجون بأدوية الستاتينات مقابلْ مجموعةِ مرضى السكري الذين لا يعالجون بأدوية الستاتينات ( 151 ± 55 مقابل 122.4 ± 34.4 ملغرام % على التوالي ، P < 0.01 ).أن متوسط القِيَم لدوال اللوحة السنية ِ،القَلَحٌ أوالتكلس السِنِّيّ ، و الْتِهابُ دَوَاعِمِ السِّنّ كَانْ أوطأ في مجموعةِ مرضى السكري الذين يعالجون بأدوية الستاتينات مِنْ مجموعةِ مرضى السكري الذين لا يعالجون بأدوية الستاتينات وكان 1.31 ± 0.57 مقابل 1.7 ± 0.5 ، P < 0.01 لدالة اللوحة السنية وكان 0.61 ± 0.47 مقابل 0.87 ± 0.65 ، P < 0.05 لدالة القلح السني وكان 2.57 ± 0.89 مقابل 3.16 ± 0.78 ، P < 0.05 لدالة دواعم السن على التوالي.الا ستنتاج : أن مرضى السكري الذين يعالجون بأدوية الستاتينات أظهروا علامات سريريةَ خاصة بمرضِ الْتِهابِ دَوَاعِمِ السِّنّ أقل مِنْ مرضى السكري الذين لا يعالجون بأدوية الستاتينات.


Article
SERUM TESTOSTERONE AND POSTPRANDIAL LIPIDS IN RELATION TO SEXUAL DYSFUNCTION IN MALE WITH CARDIOVASCULAR DISEASE

Loading...
Loading...
Abstract

Background:Earlier studies have suggested that total testosterone (Testo) concentrations influence lipid metabolism. Whether these concentrations are prospectively associated with an adverse lipid profile and an increased risk of incident dyslipidemia has not yet been investigated. Objective:Test the hypothesis that increased levels of postprandial triglycerides (TG) are associated with hypogonodism in male patients with cardiovascular disease (CVD).Methods:Forty male patients with CVD aged 30-60 years and 46 normal healthy controls were studied. Postprandial blood glucose, lipid profile, urea and creatinine were measured. In addition, Total testosterone, sex hormone binding globulin (SHBG), luteinizing hormone and follicle stimulating hormone were done by Enzyme-Linked Immuno-Sorbent Assay. Body mass index was calculated.Results:Negative correlation between Testo, and postprandial TG in both CVD and control groups was found with significant differences in Testo between these two groups, while SHBG correlated negatively with postprandial TG, in control group.Conclusion:Postprandial triglyceride levels were associated with risk of CVD. These findings are particularly interesting and may contribute to an explanation for the higher cardiovascular disease risk in men with lower total testosterone concentrations.Key words:CVD, Dyslipidemia, postprandial TG, Testosterone.


Article
Effect of atorvastatin in combination with different oral antidiabetic medications on lipid parameters and glucose level

Author: Mohammed N. Abed
Journal: Iraqi Journal of Pharmacy المجلة العراقية للصيدلة ISSN: 16802594 Year: 2013 Volume: 13 Issue: 2 Pages: 62-69
Publisher: Mosul University جامعة الموصل

Loading...
Loading...
Abstract

Background: Dyslipidemia is common in patients with type 2 diabetes mellitus and is regarded as independent risk factor for cardiovascular disease. The aim of this study was to evaluate the efficacy and safety of atorvastatin for the treatment of dyslipidemia in type 2 diabetics using either metformin or glibenclamide as oral hypoglycemic agents.Materials and methods: Fourty five type 2 diabetic patients diagnosed with dyslipidemia met the study criteria and received 20 mg/day atorvastatin, then followed after 2 months. The various biochemical parameters studied included glycated hemoglobin (HbA1c), fasting serum glucose levels (FSG), total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, very low-density lipoprotein (VLDL) cholesterol and atherogenic index (AI).Results showed that atorvastatin in both studied groups caused significant reduction in all measured parameters with an elevation in HDL, but this effect was obvious and more significant in patients using metformin than those using glibenclamide.Conclusion: This study concluded that the combination of atorvastatin and metformin was more effective on lipid profile and glucose level than atorvastatin plus glibenclamide in type 2 diabetic patients with dyslipidemia.

اعتلال الدهون يعتبر حالة شائعة في المرضى الذين يعانون من داء السكري من النوع 2، ويعتبر عامل خطر مستقل لأمراض القلب والأوعية الدموية. وكان الهدف من هذه الدراسة لتقييم فعالية وسلامة عقار أتورفاستاتين لعلاج اعتلال الدهون في مرضى السكري من النوع 2 المستخدمين إما ميتفورمين أو غليبينكلاميد كعقارات عن طريق الفم لخفض سكر الدم. تم جمع خمسة وأربعون مريضا بداء السكري نوع 2 شخصوا حديثا بالاصابة باعتلال الدهون واعطوا 20 ملغ / يوم أتورفاستاتين، ثم تلتها معاينة بعد شهرين. مختلف المعايير البيوكيميائية تم دراستها وشملت خضاب الدم المسكر، ومستويات السكر في الدم (FSG)، الكولسترول الكلي (TC)، الشحوم الثلاثية (TG)، البروتين الدهني منخفض الكثافة (LDL) ، البروتين الدهني عالي الكثافة (HDL) ، البروتين الدهني منخفض الكثافة جدا (VLDL) الكوليسترول في الدم ومؤشر تصلب الشرايين. وأظهرت النتائج أن أتورفاستاتين في كل من المجموعتين المشاركتين في الدراسة تسبب بانخفاض معنوي في جميع الفحوصات المقاسة مع ارتفاع في HDL، ولكن هذا التأثير كان واضحا وأكثر أهمية في المرضى الذين يستخدمون الميتفورمين من تلك التي تستخدم غليبينكلاميد. استنتجت هذه الدراسة أن الجمع بين أتورفاستاتين وميتفورمين كان أكثر فعالية على الدهون ومستوى السكر من أتورفاستاتين مع غليبينكلاميد في مرضى السكري من النوع 2 الذين يعانون من اعتلال الدهون.


Article
Effect of Atorvastatin And Garlic on Lipid Profile in Hyperlipidemic Patients
تأثير ال atorvastatin والثوم على مرضى فرط شحميات الدم

Authors: Zuhair M. Hussien زهير معروف حسين --- Luma T. Ahmed لمى طه أحمد --- Qutuba Gh. Hussain قتيبة غانم حسين
Journal: Diyala Journal of Medicine مجلة ديالى الطبية ISSN: 97642219 Year: 2013 Volume: 5 Issue: 1 Pages: 63-68
Publisher: Diyala University جامعة ديالى

Loading...
Loading...
Abstract

Background: Hyperlipidemia is one of the most common diseases among Iraqi community, and using herbal medicine in treating hyperlipidemia was a good choice to reduce the side effect of recommended drugs with good results of healing, Garlic (Allium sativum) has been used in herbal medicine for centuries for various health problems. It has a beneficial effect of Reducing serum lipids and cardiovascular system disease .The purpose of present study was to evaluate the effects of garlic and atorvastatine on the dyslipidemic people. Aim: The aim of this study is to assist the affectivity of the garlic in lowering the lipid profile in hyperlipidemic patients as well as the affect of time on treatment.Methods: This 12 week, Garlic treated, atorvastatin, Garlic + atorvastatin and non treated study was conducted on patients with hyperlipidemia (n=40) were divided into 4 groups each comprising 10 patients, first group was control healthy persons, second group was given garlic capsules (500mg) twice daily, third group was given atorvastatin (40mg-Gulf pharmaceutical), fourth group was given both garlic capsules + atorvastatin. Results: After 12 week the garlic + atorvastatin treated group had good results in reduction of total cholesterol (5.23±0.12) triglycerides (1.93±0.12) LDL (1.31±0.14) VLDL (0.87±0.15) as compared with those before treatment. Conclusion: This study suggests that using garlic capsules + atorvastatin in treating dyslipidemia patients are efficiently reduced serum total cholesterol, LDL,VLDL and moderately raised HDL cholesterol as compared with non-treated group ,in addition prolong duration of treatment will assess the benefit effect of garlic + atorvastatin in treatment of dyslipidemia and other cardiovascular system diseases.

المقدمة: فرط شحميات الدم ( dyslipidemia ) واحد من الأمراض الأكثر شيوعا بين المجتع العراقي واستخدام الأدوية العشبية في علاج فرط شحميات الدم كان خيارا جيدا للحد من الآثار الجانبية للعقاقير الموصى بها مع أعطائه نتائج جيدة من الشفاء، الثوم (Allium sativum) استخدم في الطب التداوي بالاعشاب لقرون لعلاج مشاكل صحية مختلفة، وله تأثير مفيد في تخفيض نسبة الدهون في الدم وأمراض القلب والأوعية الدموية. طريقة العمل: استغرق العلاج 12أسبوع ، وقد أجري على النحو التالي :عدد العينات (ن = 40) وقسمت إلى 4 مجاميع كل مجموعة تضم 10 عينات، المجموعة الأولى هي مجموعة السيطرة وتمثل الأصحاء، المجموعة الثانية (مرضى يعانون من فرط شحميات الدم )أعطوا كبسول من الثوم (حجم 500mg) مرتين يوميا ، وأعطيت المجموعة الثالثة (مرضى يعانون من فرط شحميات الدم) أتورفاستاتين (40 mg)، وأعطيت المجموعة الرابعة (مرضى يعانون من فرط شحميات) كبسول من الثوم500mg + أتورفاستاتين 40mg. النتائج: بعد 12 أسبوع من اعطاء الثوم + أتورفاستاتين ظهرت نتائج جيدة في الحد من الكولسترول الكلي (5.23 ± 0.12)TCو الدهون الثلاثية (1.93 ± 0.12) LDL (1.31 ± 0.14) VLDL (0.87 ± 0.15)TG بالمقارنة مع تلك قبل العلاج. الخلاصة: تشير هذه الدراسة إلى أن استخدام كبسول الثوم + أتورفاستاتين في علاج مرضى فرط شحميات الدم يساعد في تخفيض الكولسترول الكلي في الدم و LDLو VLDL بالمقارنة مع المجموعة غير المعالجة، بالإضافة الى إطالة مدة العلاج باستعمال الثوم + أتورفاستاتين سيعطي نتائج افضل في علاج مرضى فرط شحميات الدم. الهدف: إن الهدف من هذه الدراسة هو تقييم كفاءة استعمال الثوم مع الادوية الاخرى في خفض الدهون لمرضى فرط شحميات الدم وكذلك تأثير عامل الوقت على العلاج.


Article
Study the Effects of Ginger (Zingiber officinale) Extract on Serum Lipid in Hypothyroidism Male Rats Induce by Propylthiouracil

Authors: Nabeel M. N. Al-Sharafi --- Mohammed R.A. Al-Sharafi
Journal: Kufa Journal For Veterinary Medical Sciences مجلة الكوفة للعلوم الطبية البيطرية ISSN: 20779798 Year: 2014 Volume: 5 Issue: 2 Pages: 258-266
Publisher: University of Kufa جامعة الكوفة

Loading...
Loading...
Abstract

This study was undertaken to investigate the protective role of Ginger against the hypothyroidism induce by Propylthiouracil in male rats on serum lipids. Eighteen adult male rats were randomly divided into three equal groups (each of six) and treated as follows for four weeks, First group (C) was daily orally gavages with saline solution served as control.. Second group (G1) was daily orally gavages with Propylthiouracil (6 mg/kg B.W.). Third group (G2) was daily orally gavages with Propylthiouracil (6 mg/kg B.W.) in addition to ginger (200 mg/kg B.W.) Overnight fasting blood samples were collected from the all animals of the experiment at end week of experiment for the determination of serum triiodothyonine (T3), thyroid stimulation hormone (TSH), total cholesterol (TC), triacylglycerol (TAG), very low density lipoprotein-cholesterol (VLDL-C) and high density lipoprotein-cholesterol (HDL-C). The results showed that the A significant (P<0.05) statistical increase in the activity of TSH was observed in propylthiouracil treated groups G1 (3.72±0.73) and G2 (3.28±0.25) as compared to the control (0.0795±0.003) and A significant (P<0.05) statistical decrease in the activity of T3 in treated (G1) (2.62±0.2) as compared to the control (3.92±0.08). As well as the results show, a significant(P<0.05) elevation in serum TAG, TC and VLDL-C and decrease in HDL-C were observed in animals daily orally gavages with Propylthiouracil 6 mg/kg B.W. (G1) group as compared with control. Oral administration of ginger extract caused a non significant (P>0.05) depression in the elevated TAG and VLDL-C concentration in G2 group compared to G1 and control groups . From these results indicating that the effect of orally administration of propylthiouracil to induced hypothyroidism and induction of Dyslipidemia. On conclusions, the present study confirmed the beneficial effects of ginger extract as a hypolipidemic effects gains the dyslipidemia due to hypothyroidism.


Article
Dyslipidemia and biological agents among a sample of patients attending Baghdad Teaching Hospital

Authors: Atta AH Mousa --- Ali Hussein --- Nazar Abdull Latif
Journal: IRAQI JOURNALOF COMMUNITY MEDICINE المجلة العراقية لطب المجتمع ISSN: 16845382 Year: 2016 Volume: 29 Issue: 3 Pages: 129-132
Publisher: Al-Mustansyriah University الجامعة المستنصرية

Loading...
Loading...
Abstract

Background: Tumor necrosis factor-alpha (TNF-α) is a multifunctional pro-inflammatory cytokine that had a major role in the etio-pathogenesis of psoriasis and psoriatic arthritis, rheumatoid arthritis, inflammatory bowel disease (IBD), and other dermatologic and rheumatologic conditions. A new era in the treatment of rheumatic diseases began with the development of TNF-α-inhibitorsObjectives: To evaluate lipid profile changes after anti-TNF therapy in patients with psoriatic, rheumatoid arthritis and ankylosing spondylitis Patients & Methods: A prospective study included 90 patients presenting with ((30) Psoriatic arthritis, (30) ankylosing spondylitis (30) rheumatoid arthritis (who were treated with anti-TNF therapy (infliximab, rituxmab etanercept) and assessed during follow-up period after 6month of therapy.Results: Regarding (TC,TG, HDL and LDL) Significance differences(p<0.000) were seen after biological therapy with infliximab infusion in patients with psoriatic arthritis , The current study had Significance differences regarding TG and HDL after 6 month of treatment of rheumatoid arthritis patients with rituximab., Significance differences were seen regarding TG and LDL in ankylosing spodylitis patients treated with etanerceptConclusion: Significance differences were seen regarding lipid profile and antitumor necrosis factor alpha therapy regarding psoriatic ,Rheumatoid arthritis and ankylosing spondylitis

Listing 1 - 10 of 31 << page
of 4
>>
Sort by
Narrow your search

Resource type

article (31)


Language

English (22)

Arabic and English (8)


Year
From To Submit

2019 (1)

2018 (1)

2017 (2)

2016 (5)

2015 (7)

More...